The historical rank and industry rank for Jazz Pharmaceuticals's FCF Margin % or its related term are showing as below:
MEX:JAZZN'
s FCF Margin % Range Over the Past 10 Years
Min: 21.15 Med: 27.42 Max: 35.78
Current: 25.55
During the past 13 years, the highest FCF Margin % of Jazz Pharmaceuticals was 35.78%. The lowest was 21.15%. And the median was 27.42%.
MEX:JAZZN's FCF Margin % is ranked better than 91.76% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs MEX:JAZZN: 25.55
Jazz Pharmaceuticals FCF Margin % Related Terms
Jazz Pharmaceuticals FCF Margin % Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:JAZZN vs ASND, SMMT, BBIO: FCF Margin % Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (MEX:JAZZN) has a FCF Margin % of 36.35% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jazz Pharmaceuticals and its competitors. This is 33% above median its historical median of 27.42. Over the past decade, Jazz Pharmaceuticals' FCF Margin % has ranged from 21.15 to 35.78. According to the industry distribution chart, Jazz Pharmaceuticals ranks #79 out of 959 companies in the Biotechnology industry, placing it in the top 8.2%.
Is Jazz Pharmaceuticals' FCF Margin % too high?
Jazz Pharmaceuticals' current FCF Margin % of 36.35% is 33% above median its 10-year median of 27.42. Over the past 10 years, this metric has ranged from a low of 21.15 to a high of 35.78. Based on the distribution chart, Jazz Pharmaceuticals ranks #79 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' FCF Margin % compare to ASND and SMMT?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #79 out of 959 companies for FCF Margin %. This places Jazz Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. Historically, Jazz Pharmaceuticals' own FCF Margin % has ranged from 21.15 to 35.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current FCF Margin % is 36.35%, which is 33% above median its own 10-year median of 27.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Jazz Pharmaceuticals (MEX:JAZZN) has a current FCF Margin % of 36.35%. The stock's GF Value™ is MXN1,641.59, compared to a current price of MXN2,500.00 — trading 52.3% above its estimated fair value. The current FCF Margin % is 36.35%, which is 33% above median its 10-year median of 27.42. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Jazz Pharmaceuticals (MEX:JAZZN), the current FCF Margin % is 36.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (MEX:JAZZN) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN2,500.00 is trading 52.3% above its estimated GF Value™ of MXN1,641.59.
Key valuation signals for MEX:JAZZN:
FCF Margin %: 36.35% (33% above median its 10-year median of 27.42)
GF Value™: MXN1,641.59 vs. price of MXN2,500.00 (52.3% above fair value)
No single metric tells the full story. See the MEX:JAZZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for MEX:JAZZN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:JAZZN has been successfully added to your 
